Australia

Found 8,137 articles

• Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

  4/14/2023

  Incannex Healthcare Ltd is pleased to announce that is has appointed Quest Pharmaceutical Services (‘QPS’) to provide regulatory advice and manage clinical trials for the development of CannQuit™ and ReneCann™ products for addiction and immune-disordered skin diseases.

• Novotech Joins Expert Panel at AACR for eChinaHealth Session on Collaborating with China’s Cancer Research Sector

  4/13/2023

  Novotech, the leading Asia Pacific centred biotech CRO joins oncology leaders at the eChinaHealth panelist session and dinner at AACR.

• Saluda Medical Announces $150M Equity Financing Led by Wellington Management with Fidelity Management & Research Company and TPG

  4/13/2023

  Saluda Medical Inc. announced the closing of a US $150 million equity financing round led by new investor Wellington Management, with strong support from current investor Fidelity Management & Research Company and new investor TPG.

• AVITA Medical Announces Update to Automation Device

  4/13/2023

  AVITA Medical, Inc. announced that its automated device, RECELL GO, maintains the Food and Drug Administration Breakthrough Device designation for the treatment of acute wounds.

• SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases

  4/12/2023

  SciNeuro Pharmaceuticals today announced that SNP318, a novel Lp-PLA2 inhibitor, is advancing into Phase 1 clinical trials in Australia, positioning it for global development.

• Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

  4/11/2023

  Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “ Process for Preparation of Biologically Active Copolymer ,” with expiry in 2041.

• Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

  4/11/2023

  Bone Biologics Corporation announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.

• Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-upTop-line phase 2 trial data shows disease modifying potential and pain reduction

  4/11/2023

  Australia’s Paradigm Biopharmaceuticals Ltd says analysis of six-month trial data shows injectable pentosan polysulfate sodium may slow the progression of osteoarthritis of the knee.

• Q3 FY23 Business Update Webinar Notification

  4/11/2023

  Immuron Limited is pleased to advise it will provide a business update for the quarter ended 31 March 2023.

• Recce Pharmaceuticals Receives Further A$973,144 Research and Development (R&D) Advance

  4/6/2023

  Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it received additional non-dilutive funds from Radium Capital for A$973,144 for Recce’s future research and development tax incentive.

• Immuron Q3 Sales reach 150% of 1H Sales

  4/6/2023

  Immuron Limited is pleased to announce the Q3 FY23 sales* results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

• Auditory Processing Institute Study Finds Long COVID 'Brain Fog' Linked to Auditory Processing Disorder, an Underdiagnosed Neurological Disorder

  4/5/2023

  Long COVID "brain fog" symptoms are linked to auditory processing disorder (APD), an underdiagnosed neurological disorder, suggests a new study from the Auditory Processing Institute of Queensland, Australia, published today in The Hearing Journal.

• Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis

  4/5/2023

  Immunexpress, Pty Ltd. announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID as a tool to determine sepsis status in patients admitted to the Intensive Care Unit (ICU).

• Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

  4/4/2023

  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA).

• Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

  3/31/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023.

• Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

  3/30/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) today announces it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line non- small cell lung cancer (1L NSCLC).

• Ease-of-Use and Potential Self-Administration of Vaccination Shown with Vaxxas High Density Microarray Patch (HD-MAP)

  3/30/2023

  Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration.

• Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference

  3/30/2023

  Actinogen Medical ASX: ACW ("ACW" or "the Company") is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD™ 2023) later today in Gothenburg, Sweden.

• Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours

  3/28/2023

  Grey Wolf Therapeutics today announced dosing of the first patient in the initial monotherapy module of an adaptive Phase 1/2 clinical trial evaluating GRWD5769, the company's investigational first-in-class ERAP1 inhibitor.

• HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR

  3/28/2023

  HaemaLogiX Ltd announced that its anti-KMA CAR-T cell preclinical development has been completed and is the subject of an abstract accepted for poster presentation at the 2023 Annual Meeting of the American Association for Cancer Research, held 14-19 April in Orange County.